| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |